Improved myocardial perfusion preceding clinical response on bosentan treatment for coronary vasospasm.

Vermeltfoort, I. A. C., Raijmakers, P. G. H. M. & Kamphuisen, P. W., 1-Jun-2009, In : Acta cardiologica. 64, 3, p. 415-417 3 p.

Research output: Contribution to journalArticleAcademicpeer-review

Many patients suffer from persistent angina due to coronary vasospasm despite optimal medical treatment. We treated a 46-year-old patient with severe and treatment-resistant coronary vasospasm with the endothelin-receptor antagonist bosentan. Using oxygen-15-labelled water in conjunction with oxygen 15-labelled carbon monoxide positron emission tomography (PET), we measured an impaired coronary flow reserve (CFR) in 6 out of 13 segments directly before the start of bosentan therapy. A repeated PET measurement after 16 weeks of bosentan revealed a completely normalized CFR in this patient. Furthermore, the patient reported less frequent and less severe chest pain. Our data suggest a potential role of endothelin-receptor antagonists for patients with severe coronary vasospasms.
Original languageEnglish
Pages (from-to)415-417
Number of pages3
JournalActa cardiologica
Issue number3
Publication statusPublished - 1-Jun-2009


  • antihypertensive agent, bosentan, sulfonamide, article, blood flow velocity, case report, coronary artery spasm, fractional flow reserve, human, male, middle aged, myocardial perfusion imaging, pathophysiology, positron emission tomography, variant angina pectoris

ID: 17446395